High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens
High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens
复制标题
DOI：
10.1007/s10238-015-0403-0
复制
发表时间：
2017-02-01
影响因子：
4.6
通讯作者：
Ueyama, Yoshiya
中科院分区：
文献类型：
--
作者：
Harada, Koji;Ferdous, Tarannum;Ueyama, Yoshiya
Stathmin 1是一种癌蛋白，通过调节微管动力学来调节细胞周期，并可在突变状态下导致细胞不受控制的增殖。应用免疫组织化学方法检测49例口腔鳞状细胞癌(OSCC)患者接受多西紫杉醇(Doc)化疗后stathmin1的表达。此外，我们还探讨了stathmin-1的表达与上述患者的临床病理特征及预后的关系。虽然Stathmin 1在口腔鳞癌组织中的表达水平不同，但在肿瘤细胞胞浆中仍可检测到。在口腔鳞癌中，Stathmin 1的表达与患者性别、年龄无关。而Stathmin-1的表达与T分期(P=0.0017)、N分期(P=0.0171)、分期(P<；0.0001)、疗效(P<；0.0001)和患者预后(P=0.0387)显著相关。此外，肿瘤细胞中Stathmin1的高表达与总生存期缩短有关(OS，P=0.0017)。多因素分析还显示，Stathmin1的高表达是生存率降低的预测因素(P=0.0241)。这些结果提示，口腔鳞状细胞癌患者在用含Doc方案治疗时，stathmin 1高表达的患者可能疗效较差，临床预后较差。
Stathmin 1 is an oncoprotein that regulates cell cycle by modulating microtubule dynamics and can cause uncontrolled cell proliferation in mutated state. The present study examined stathmin 1 expression in 49 patients with oral squamous cell carcinoma (OSCC) treated with docetaxel (Doc)-containing regimens by immunohistochemical staining. Moreover, we investigated the relationship between stathmin 1 expression and clinicopathological features, as well as the prognosis of above patients. Stathmin 1 could be detected in the cytoplasm of tumor cells in OSCC tissues though its expression level was variable. There was no correlation between stathmin 1 expression and patient gender, or age in OSCC. However, stathmin 1 expression of tumor cell was significantly correlated with T classification (P = 0.0017), N classification (P = 0.0171), stage (P < 0.0001), therapeutic efficacy (P < 0.0001), and patient outcome (P = 0.0387). In addition, high expression of stathmin 1 in tumor cells was associated with shorter overall survival (OS, P = 0.0017). Multivariate analysis also revealed that high expression of stathmin 1 was a predictor of reduced survival (P = 0.0241). These findings suggest that patients with OSCC tumors showing high expression of stathmin 1 might have poor therapeutic effects and worse clinical outcomes in OSCC treated with Doc-containing regimen.